• Moberg Derma AB, of Stockholm, Sweden, said the German-Federal Institute for Drugs and Medical Devices granted approval for a Phase I trial of Limtop, a product in development for actinic keratosis, genital warts and basal cell carcinoma. The drug is a new formulation of an immunomodulatory compound that has shown improved delivery to skin tissue in preclinical studies.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST